The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Study ID
NCT06117644
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a single-center, prospective, single-arm study of the efficacy of double-dose Furmonertinib in the treatment of patients with slow Osimertinib-resistant non-small cell lung cancer, mainly in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations in stage IIIB or IV, slow drug resistance after treatment with Osimertinib, and no therapeutic target was found by secondary biopsy after drug resistance.

Key Dates

Start date
Nov 1, 2023
Status verified
Oct 2023
Primary completion
Nov 1, 2025
Completion
Oct 1, 2026

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: Furmonertinib
    The subjects will be treated with Furmonertinib (double dose, 160mg). The subjects were treated with drugs for 24 months until the tumor progressed (worsened) or died.

Primary Outcome Measure

ORR [ Time Frame: Observation time 1-2 months. ]

Central Contacts

Related Studies